South Africa's rand falls as Omicron worries linger



JOHANNESBURG, Nov 30 (Reuters) - The South African rand retreated early on Tuesday as caution lingered in markets after the discovery of a COVID-19 variant that is spreading in the country and globally.

At 0625 GMT, the rand ZAR= traded at 16.2150 against the dollar, 0.46% weaker than its previous close.

The currency plunged to its weakest since October 2020 on Friday as the world reacted with alarm to the news of the new variant, Omicron, which was first detected in southern Africa.

"The short-term technical indicators remain in overbought territory, but caution is advised, as headlines remain significant market drivers and liquidity is limited," analysts at Nedbank said in a note.

A South African infectious disease expert said on Monday that the country's COVID-19 infection rate could triple to more than 10,000 by the end of this week as the Omicron variant spreads rapidly. But little is known yet about the new variant.

In fixed income, the yield on the benchmark 2030 ZAR2030= maturity dipped 2 basis points to 9.84% in early deals.
Reporting by Olivia Kumwenda-Mtambo; Editing by Kim Coghill

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.